


Initial “*motif search*” on TADs

E coli genomic
DNA



DBD

Gal4

LexA

Yeast:

*GAL4*Δ



blue colonies

- 15000 transformants
- 0.1-1% function as TA.
- 12 to 81 aa
- Negative charge

Ma & Ptashne, 1987 (Cell)
Ruden et al., 1991 (Nature)

Small molecules mimicking TADs




Figure 2. Isoxazolidine-based activation domains. (a) Five isoxazolidines (2–6) bearing functional groups commonly found in natural activation domains were targeted. (b) Synthetic strategy used to prepare isoxazolidines. (c) Results from in vitro transcription assays. The activity of each compound represents the average of at least three individual experiments with the indicated error (SDOM). For details see the Supporting Information.

TAD motif?

Supplementation table

Supplemented
Oaf1/Pip2/Gal4 pattern:

p1:		GSTYW DENQRKH
p2:	FLIVAM	+ YW DENQ
p3:	FLIVAM	+ GSTYW
p4:	FLIVAM	+ YW DENQ
p5:	FLIVAM	+ GSTYW DENQRKH
p6:	FLIVAM	+ YW DENQ
p7:	FLIVAM	+ GSTYW
p8:	FLIVAM	+ GSTYW DENQRKH
p9:	FLIVAM	+ GSTYW DENQRKH

D

Oaf1/Pip2/Gal4 9aa TAD pattern


[GSTYW DENQRKH] [FLIVAMYW DENQ] [FLIVAMSTYW] [FLIVAMYW DENQ]
[FLIVAMGSTYW DENQRKH] [FLIVAMYW DENQ] [FLIVAMSTYW]
[FLIVAMGSTYW DENQRKH] [FLIVAMGSTYW DENQRKH]

Yeast 9aa TAD pattern

[GSTDENQWYM] {KRHC GP} [FLIVMW] {KRHC GP} {CGP}
{KRHC GP} [FLIVMW] [FLIVAMW] {KRHC P}

Animal 9aa TAD pattern


[GSTDENQWYM] {KRHC GP} [FLIVMW] {KRHC GP}
{CGP} {CGP} [FLIVMW] {CGP} {CGP}




And yet... it's not clear what TADs have in common.

- **Assumption:**
There are patterns or motifs common to all TADs.
- **Plan:**
Use *state of the art* experimental and computational methodologies to analyze a big combinatorial space of TAD sequences to find motifs or patterns.


Workflow




Bottleneck is yeast transformation





Strategy for high throughput isolation of activation domains



FACS selection of TAD libraries





Splitting novel ADs on their strength



Library sequencing

Platform: HiSeq Illumina (paired end) - 100nt reads with 7nt overlap



HT-seq analysis

- **PAIR READS** (FLASH, PMID: 21903629)
 - **TRANSLATION TO AMINO ACID** (custom script)
 - **CLUSTER SEQUENCES** (USEARCH, PMID: 20709691) - sequences are redundant, probably due to random technical errors. Clusters allow up to 6 mismatches (20%).
 - **SCORE SEQUENCES** based on number or reads/bin
 - **PREDICT PHYSICOCHEMICAL PROPERTIES OF 30mers** (*intrinsic disorder*: IUPred, *Secondary Structure*: PSIPRED, *GRAVY scores*: custom scripts)
-
- **DEEP LEARNING...** you?
 - Tried MEME and Gibbs sampler without success...

Translation to Amino-acids

(inspect the raw reads in FastaQC program followed by custom scripts – Qual offset=33, HiSeq Illumina v. >1.8)


- Include filters for:

- Early-stop (0.9 – 40%)
- no5-primer (~3%)
- no3-primer (5-25%)
- Frame-shift (~0.3%)
- Low-quality_{Phred=30} (15-35%)
- Short-seq (0.2-20%)

<5 reads (all bins) → discarded

Positives: $\text{bins}(3,4) > 2 * \text{bins}(0,1,2)$ ~20000

Negatives: $\text{bins}(0) > 2 * \text{bins}(2,3,4)$ ~20000



Remove sequence redundancy that might arise from technical errors

USEARCH



find clusters





Low reads seqs
Merged into few
Seqs with
high # reads



	cov	pid	1	[.	.]	31																							
1 c3afcfff061	100.0%	100.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	Y	G	
2 a8d179d622	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	Y	D	
3 96118b063f	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	L	D	
4 81ba449f95	100.0%	86.7%	-	S	R	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D
5 3bad4284a8	100.0%	86.7%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
6 43ad44b018	96.7%	82.8%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
7 ca93f851f2	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
8 baa4600d5f	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
9 d7c9172650	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
10 3e7c810844	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
11 26441c61af	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
12 36de8fa636	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
13 4257f9a990	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
14 eed726c560	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
15 7a2dd2d7ee	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
16 4bea20ceb3	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
17 7a19e29bd4	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
18 db65b2a79c	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
19 01fbb47b80	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
20 811ba3fe07	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
21 a64eeb5569	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
22 b20799cacc	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
23 3905e0e95d	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
24 0e76b223b0	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
25 55775b4eef	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
26 024546b7fa	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
27 608eabc162	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
28 e941ed9adf	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
29 ee68cfa6c8	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
30 72c02e20e0	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
31 65cf78b7b6	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
32 f66ab7ab81	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
33 dd04955007	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
34 af2f1138be	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
35 d1029dae21	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
36 92b1db902c	100.0%	96.7%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
37 a95f4f86c5	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
38 1b43d1223f	100.0%	93.3%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
39 901e37d008	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
40 0fbf123889	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
41 b776b6349a	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
42 ebd6a5c6d5	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
43 786f2800d3	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
44 a8908d1e3b	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
45 2288c2bb66	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
46 f963cc8b21	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
47 b29fbe95ce	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
48 387a759ab3	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
49 88dbb3444e	100.0%	87.1%	D	S	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D
50 3e5d6f882f	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	
51 bc40f29d50	100.0%	90.0%	-	S	R	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D
52 4b7c2a4f4c	100.0%	90.0%	-	S	F	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D
53 7bdd32f805	100.0%	90.0%	-	S	A	L	C	R	N	A	I	R	S	E	L	Y	Y	W	D	P	P	Y	Q	L	R	S	T	V	H	D	

Scoring the sequences

Based on 18 mutants experimentally validated and with known distribution of reads across Bin1-4 and Bkgd



Enrichment in aa content



Features for ML

- AA seq
- AA hydrophobicity
- AA Charge
- AA Secondary Structure
- AA Disorder

Regression with a Dense model without regularization

Layer (type)	Output Shape	Param #
=====		
dense_1 (Dense)	(None, 500)	3500

dense_2 (Dense)	(None, 250)	125250


dense_3 (Dense)	(None, 60)	15060

dense_4 (Dense)	(None, 1)	61
=====		

Total params: 143,871

Trainable params: 143,871



Non-trainable params: 0



Regression with Convolutional model

Layer (type)	Output Shape	Param #
input_1 (InputLayer)	(None, 60, 1)	0
conv1d_1 (Conv1D)	(None, 60, 100)	1100
conv1d_2 (Conv1D)	(None, 60, 100)	100100
dropout_1 (Dropout)	(None, 60, 100)	0
max_pooling1d_1 (MaxPooling1	(None, 30, 100)	0
dropout_2 (Dropout)	(None, 30, 100)	0
flatten_1 (Flatten)	(None, 3000)	0
dense_1 (Dense)	(None, 500)	1500500
batch_normalization_1 (Batch	(None, 500)	2000
dense_2 (Dense)	(None, 100)	50100
batch_normalization_2 (Batch	(None, 100)	400
dense_3 (Dense)	(None, 50)	5050
batch_normalization_3 (Batch	(None, 50)	200
dense_4 (Dense)	(None, 1)	51

Total params: 1,659,501
 Trainable params: 1,658,201
 Non-trainable params: 1,300



Classification using convolutional or recurrent models

- Sigmoid activation in output layer
- Loss = binary crossentropy
- Best. accuracy = 0.68 ± 0.06
(benchmark ~50%)

Hyper-parameters tuning

- GridSearchCV(sklearn)
- batch_size = [64, 128, 256]
- epochs = [10]
- kernel_init = ['uniform', 'normal']
- pDropout = [0.3-0.5]
- Convolutions2D_shape1= [3,2]
- learning_rate = [0.01, 0.0001] #0.1, 0.01, 0.001]
- Optimizer = ['RMSprop', 'Adam']
- decay = [1e-4, 1e-6]

Questions

- Stacking ohe-AA and other features into a nD tensor?
- Keeping aa-Ids and other features separately?
- Working with 1D or nD tensors? This for convolutional models and RNN.
- Embedding layers?

Library design and construction

- ✓ **NNN** → 3 out of 64 (~5%) are stop codons... → short peptides rather than 30 residues long sequence
- ✓ **NNK** or **NNS** → > 3% stop codons
- ✓ **NNY** and **RNN** repeats (Y=pyrimidines, R=purines) avoid Stop codon but do not encode for 2 amino-acids
- ✓ **SOLUTION**: Biasing the **ratios of nucleotides** at all three positions in the randomized codons.

• Codon Optimized Libraries

	A	C	G	T
0	0.26	0.26	0.24	0.21
1	0.38	0.19	0.17	0.22
2	0.00	0.46	0.34	0.16

- Optimized for Equal Ratios
- Optimized for Disordered regions

	Ideal	Optimized
F	0,05	0,035
L	0,05	0,08
I	0,05	0,045
M	0,05	0,03
V	0,05	0,065
S	0,05	0,08
P	0,05	0,04
T	0,05	0,05
A	0,05	0,045
Y	0,05	0,04
H	0,05	0,04
Q	0,05	0,03
N	0,05	0,055
K	0,05	0,04
D	0,05	0,045
E	0,05	0,035
C	0,05	0,03
W	0,05	0,025
R	0,05	0,085
G	0,05	0,06
STOP	0	0,03

Searching nucleotide composition space

- Space of all possible sets of 3 nucleotide mixture $X_1X_2X_3$
- Each point in nucleotide space specifies a list of probabilities for the codons and therefore values for aminoacids and stop codons frequencies.
- Difference between **target** values and the **encoded** amino acid ratios correspond to a cost that we seek to minimize

SPACE


$$C = \sum_{i=1}^{21} (t_i - e_i)^2$$

Surface, where the deepest valley contains the nucleotide composition that most closely match the design target.

Complete enumeration of the space

Possible values for each
dimension of space

Number of possible compositions


$$N = \frac{\sum_{i=1}^{n+1} i(i+1)}{2}$$

1% resolution = 100 possible values

~174000 compositions for one nucleotide

~10¹⁵ possible 3-based combinations

~30 years to test all possible combinations

Scatter plot – design vs experimental

MEME


DISCOVERED MOTIFS

	Logo	E-value ?	Sites ?	Width ?
1.		3.1e+612	19086	7
2.		1.3e+1017	19086	6
3.		1.2e+1299	19086	6

Other Settings


Motif Site Distribution	OOPS: Exactly one site per sequence
Objective Function	E-value of product of p-values
Starting Point Function	E-value of product of p-values
Site Strand Handling	This alphabet only has one strand
Maximum Number of Motifs	3
Motif E-value Threshold	no limit
Minimum Motif Width	6
Maximum Motif Width	29
Minimum Sites per Motif	19086
Maximum Sites per Motif	19086
Bias on Number of Sites	0.8
Sequence Prior	Dirichlet Mixture
Sequence Prior Source	prior30.plib
Sequence Prior Strength	intrinsic strength
EM Starting Point Source	From substrings in input sequences
EM Starting Point Map Type	Point Accepted Mutation
EM Starting Point Fuzz	120
EM Maximum Iterations	50
EM Improvement Threshold	0.00001
Maximum Search Size	100000
Maximum Number of Sites for E-values	1000
Trim Gap Open Cost	11
Trim Gap Extend Cost	1
End Gap Treatment	Same cost as other gaps

Gibbs sampler





Batch size, not just a matter of learning speed?

0.41 ± 0.29 {'batch_size': 64, 'decay': 1e-06, 'epochs': 10, 'init': 'uniform', 'k1': 3, 'lr': 0.001, 'pDrop': 0.4}
 0.68 ± 0.07 {'batch_size': 128, 'decay': 1e-06, 'epochs': 10, 'init': 'uniform', 'k1': 3, 'lr': 0.001, 'pDrop': 0.4}
 0.55 ± 0.15 {'batch_size': 256, 'decay': 1e-06, 'epochs': 10, 'init': 'uniform', 'k1': 3, 'lr': 0.001, 'pDrop': 0.4}





Amino-acid content of positive and negative sets



Unique sequences

Average aa content per sequence



Unique sequences